In those studies, 1-year maintenance treatment with 150–300 mg/day of nilotinib resulted in a significant reduction in the cerebrospinal fluid (CSF) level of hyperphosphorylated tau and an incremental change in the CSF level of dopamine metabolites in PD as well as a reduction in the CSF level of phosphorylated-tau-181 and amyloid beta 40 and 42 and the rate of hippocampal volume loss in AD17,18. Here, MAPT is linked to Parkinson disease.